Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 14/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 14/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22521404 | 1.00 | PRMT5 (0.34) | PRMT5WDR77HRH2HTR5AFGFR1 | |
| SCHEMBL23429787 | 1.00 | PRMT5 (0.34) | PRMT5WDR77HRH2HTR5AFGFR1 | |
| SCHEMBL27188768 | 1.00 | PRMT5 (0.34) | PRMT5WDR77HRH2HTR5AFGFR1 | |
| SCHEMBL21061526 | 1.00 | PRMT5 (0.34) | PRMT5WDR77HRH2HTR5AFGFR1 | |
| SCHEMBL22521591 | 0.90 | PRMT5 (0.32) | PRMT5WDR77HRH2HTR5A | |
| SCHEMBL21061459 | 0.90 | PRMT5 (0.38) | PRMT5WDR77HRH2HTR5AFGFR1 | |
| SCHEMBL23430001 | 0.90 | PRMT5 (0.38) | PRMT5WDR77HRH2HTR5AFGFR1 | |
| SCHEMBL27188770 | 0.89 | PRMT5 (0.37) | PRMT5WDR77 | |
| SCHEMBL21130083 | 0.89 | PRMT5 (0.37) | PRMT5WDR77 | |
| SCHEMBL23430012 | 0.88 | PRMT5 (0.42) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391695-B2 | PRMT5 inhibitors | LUPIN LIMITED (IN) | 2025-08-19 | — | — | US | disclosed |
| CN-114026094-B | PRMT5 inhibitors | 印度鲁宾有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | LUPIN LIMITED (IN) | 2024-04-09 | — | — | US | disclosed |
| EP-3980417-B1 | PRMT5 INHIBITORS | LUPIN LTD (IN) | 2023-09-27 | — | — | EP | disclosed |
| US-20220315589-A1 | PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2022-10-06 | — | — | US | disclosed |
| US-11459330-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | LUPIN LIMITED (IN) | 2022-10-04 | — | — | US | disclosed |
| US-20220267339-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2022-08-25 | — | — | US | disclosed |
| EP-3724190-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | LUPIN LTD (IN) | 2022-07-06 | — | — | EP | disclosed |
| EP-3980417-A1 | PRMT5 INHIBITORS | Lupin Limited (IN) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459330-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 123/4885HRH2 3175/4885 |
| US-20220315589-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 176/4885HRH2 3877/4885 |
| US-12391695-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 176/4885HRH2 3877/4885 |
| US-20220267339-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 123/4885HRH2 3175/4885 |
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 123/4885HRH2 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.